Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>=18 years.~2. Histologically-confirmed NSCLC (adenocarcinoma, large cell, and undifferentiated). Patients with squamous histology are not eligible.~3. Life expectancy of at least 12 weeks.~4. Patients with the following stages of NSCLC:~   * T2 N0 tumors: Limited to tumors \>=4 cm.~  * T1-2 N1 tumors.~  * T3 N0-1 tumors (excluding superior sulcus tumors): Including tumors involving the chest wall, proximal airway, or mediastinal pleura where preoperative RT is not planned.~  * T1-2 N2 tumors: For patients with N2 disease involving 1 zone (Upper zone (R), AP zone (L), subcarinal zone, or lower zone) and nodes \<=2 cm in diameter.~  * T4 N0-1 tumors (excluding superior sulcus tumors): T4 lesions, other than malignant effusions where radiotherapy is not planned.~5. Patients with clinical N2 involvement must have histologic confirmation by mediastinoscopy (or alternate biopsy procedure).~6. Tumors should be considered potentially resectable.~7. No evidence of extrathoracic metastatic disease.~8. Patients must have measurable disease by RECIST version 1.1 criteria.~9. Patients must be candidates (medically) for chemotherapy followed by surgical resection.~10. Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of a minor surgery (with the exception of portacath or other central access catheter placement); at least 4 weeks must have elapsed from the time of a major surgery.~11. Laboratory values as follows:~    * Absolute neutrophil count (ANC) \>=1500/µL~   * Hemoglobin (Hgb) \>=9 g/dL~   * Platelets \>=100,000/uL~   * AST/SGOT and ALT/SGPT within normal limits (WNL)~   * Total bilirubin within normal limits (WNL)~   * Creatinine \<=1.5 mg/dL~12. ECOG Performance Status grade 0 or 1.~13. Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.~14. Patient must be accessible for treatment and follow-up.~15. Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.~Exclusion Criteria:~1. Mixed small-cell and non-small cell histologies.~2. Pulmonary carcinoid tumors.~3. History of prior malignancy within 3 years, with the exception of non-melanoma skin cancer or carcinoma in situ.~4. Peripheral neuropathy \>= grade 1.~5. Patients receiving thrombolytic therapy within 10 days of starting study treatment are ineligible. Therapeutic anticoagulation is allowed if the anticoagulant dosing is stable.~6. History of acute myocardial infarction or unstable angina within 6 months prior to Day 1 of study treatment.~7. History of or stroke or ischemic attack within 6 months prior to Day 1 of study treatment.~8. Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) in spite of medical management.~9. New York Heart Association (NYHA) class II or greater congestive heart failure (CHF).~10. Patients with significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of study treatment.~11. Any prior history of hypertensive crisis or hypertensive encephalopathy.~12. Patients with hematemesis or hemoptysis (\>=1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 of study treatment.~13. Proteinuria at screening, as demonstrated by either:~    * Urine protein: creatinine (UPC) ratio \>=1.0 (see Appendix A) at screening, or~   * Urine dipstick for proteinuria \>=2+ (patients discovered to have \>=2+ proteinuria on dipstick analysis should undergo a 24-hour urine collection and must have \<=1g of protein in 24 hours to be eligible).~14. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.~15. Patients with evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).~16. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1 of study treatment.~17. Women who are pregnant (positive pregnancy test) or lactating.~18. Use of any non-approved or investigational agent within 28 days of administration of the first dose of study drug.~19. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.~20. Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.~21. History of hypersensitivity to active or inactive excipients of any component of treatment.~22. Inability to comply with study and/or follow-up procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin/Paclitaxel/Bevacizumab (Type: EXPERIMENTAL): Preoperative chemotherapy and bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues